

**Data for figures 1 to 7 in the Addendum to the Assessment Report: cost-effectiveness of interventions by absolute annual fracture risk for women with no clinical risk factors**

Cost per QALY (£) for women aged 50 – 54 (Figure 1)

T-Score	-5	-4.5	-4	-3.5	-3	-2.5	-2	-1.5	-1	-0.5	0	0.5	1
Absolute Risk	5.95%	3.55%	2.26%	1.55%	1.14%	0.89%	0.72%	0.61%	0.52%	0.47%	0.44%	0.42%	0.40%
Alendronate	-1,669	5,299	17,482	37,568	67,987	109,614	160,607	217,247	276,132	327,920	358,938	384,894	407,748
Risedronate	1,154	10,179	25,335	48,933	82,159	124,125	171,903	222,292	273,444	317,525	342,507	364,116	383,827
Etidronate	80,442	91,108	102,996	116,314	131,139	147,819	166,595	187,734	211,537	232,509	242,489	252,875	263,683
Strontium ranelate	9,175	24,225	48,533	84,459	132,033	188,614	250,082	313,268	377,107	431,762	461,632	488,232	513,137
Raloxifene	229,920	260,118	293,777	331,487	373,465	420,694	473,858	533,716	601,115	660,499	688,756	718,167	748,768
Raloxifene*	38,553	34,742	30,986	27,412	24,094	21,068	18,345	15,917	13,769	11,872	10,204	8,753	7,492

Cost per QALY (£) for women aged 55 – 59 (Figure 2)

T-Score	-5	-4.5	-4	-3.5	-3	-2.5	-2	-1.5	-1	-0.5	0	0.5	1
Absolute Risk	5.47%	3.47%	2.33%	1.66%	1.24%	0.98%	0.79%	0.66%	0.56%	0.51%	0.48%	0.45%	0.43%
Alendronate	-305	7,055	18,622	35,651	58,734	87,592	121,039	157,693	196,666	223,617	245,447	265,407	284,336
Risedronate	3,019	12,190	25,950	45,095	69,496	98,313	130,286	164,456	200,515	224,322	243,646	261,752	279,316
Etidronate	42,285	48,579	55,712	63,823	72,954	83,364	95,236	108,777	124,224	132,977	140,541	148,521	156,936
Strontium ranelate	12,107	26,308	46,493	72,915	104,636	140,344	178,804	219,463	262,509	289,847	312,213	333,704	354,987
Raloxifene	121,928	139,748	159,946	182,912	208,766	238,241	271,857	310,200	353,937	378,722	400,141	422,736	446,565
Raloxifene*	37,131	34,743	31,979	29,030	26,047	23,152	20,419	17,894	15,598	13,502	11,649	10,024	8,603

Data for Figures 1 – 14 of the Addendum to the Assessment Report

Cost per QALY (£) for women aged 60 – 64 (Figure 3)

T-Score	-5	-4.5	-4	-3.5	-3	-2.5	-2	-1.5	-1	-0.5	0	0.5	1
Absolute Risk	5.33%	3.54%	2.46%	1.78%	1.34%	1.05%	0.85%	0.70%	0.60%	0.54%	0.50%	0.46%	0.43%
Alendronate	599	7,306	17,462	32,111	51,923	77,274	107,925	143,319	178,474	205,708	231,292	255,654	279,364
Risedronate	3,917	12,152	24,084	40,430	61,345	86,755	116,197	149,223	180,991	204,443	226,691	248,244	269,618
Etidronate	40,781	47,466	55,159	64,030	74,083	85,694	99,107	114,604	128,942	138,090	147,871	158,327	169,502
Strontium ranelate	13,035	25,775	43,462	66,587	94,847	127,903	165,209	206,487	245,458	273,242	300,012	326,411	353,018
Raloxifene	117,643	136,571	158,352	183,471	211,936	244,811	282,791	326,673	367,270	393,174	420,870	450,476	482,118
Raloxifene*	41,252	39,219	36,581	33,563	30,359	27,152	24,059	21,157	18,462	16,002	13,828	11,913	10,234

Cost per QALY (£) for women aged 65 – 69 (Figure 4)

T-Score	-5	-4.5	-4	-3.5	-3	-2.5	-2	-1.5	-1	-0.5	0	0.5	1
Absolute Risk	5.88%	4.14%	3.01%	2.25%	1.73%	1.37%	1.10%	0.90%	0.79%	0.71%	0.65%	0.59%	0.54%
Alendronate	-32	5,817	13,989	24,980	39,064	56,521	77,448	101,895	122,196	141,530	160,714	179,922	199,411
Risedronate	3,212	10,177	19,555	31,687	46,652	64,606	85,591	109,700	128,760	146,748	164,718	182,904	201,572
Etidronate	22,025	26,070	30,793	36,314	42,664	50,094	58,790	68,968	75,589	82,065	89,081	96,680	104,910
Strontium ranelate	11,581	21,514	34,322	50,211	69,086	91,106	116,378	145,149	166,799	187,197	207,846	229,047	251,100
Raloxifene	64,555	76,007	89,379	105,012	122,992	144,031	168,653	197,472	216,218	234,556	254,422	275,940	299,243
Raloxifene*	35,042	35,481	35,049	33,819	31,916	29,561	26,942	24,223	21,384	18,745	16,346	14,187	12,259

Cost per QALY (£) for women aged 70 – 74 (Figure 5)

T-Score	-5	-4.5	-4	-3.5	-3	-2.5	-2	-1.5	-1	-0.5	0	0.5	1
Absolute Risk	7.03%	5.20%	3.93%	3.02%	2.37%	1.88%	1.51%	1.26%	1.12%	0.99%	0.89%	0.80%	0.72%
Alendronate	-562	3,977	9,783	17,046	25,775	36,236	48,614	61,445	72,390	83,955	95,953	108,485	121,682
Risedronate	2,231	7,294	13,580	21,231	30,198	40,755	53,088	65,606	75,926	86,888	98,330	110,371	123,149
Etidronate	11,702	14,144	17,035	20,462	24,382	29,023	34,518	39,823	43,702	48,127	52,985	58,316	64,166
Strontium ranelate	8,867	15,474	23,465	32,986	43,941	56,708	71,551	86,359	98,174	110,878	124,275	138,518	153,767
Raloxifene	35,327	42,241	50,429	60,132	71,230	84,369	99,928	114,947	125,930	138,460	152,214	167,310	183,874
Raloxifene*	25,798	28,055	29,783	30,814	30,969	30,356	29,058	27,023	24,483	21,972	19,536	17,226	15,078

Data for Figures 1 – 14 of the Addendum to the Assessment Report

Cost per QALY (£) for women aged 75 – 79 (Figure 6)

T-Score	-5	-4.5	-4	-3.5	-3	-2.5	-2	-1.5	-1	-0.5	0	0.5	1
Absolute Risk	8.46%	6.38%	4.87%	3.76%	2.94%	2.32%	1.85%	1.58%	1.37%	1.20%	1.06%	0.93%	0.83%
Alendronate	-2,823	918	5,639	11,543	18,652	27,331	37,857	47,445	57,438	68,515	80,426	93,245	107,076
Risedronate	-126	4,050	9,209	15,535	23,003	31,987	42,756	52,139	61,791	72,491	83,998	96,413	109,858
Etidronate	9,101	11,216	13,755	16,805	20,293	24,470	29,474	33,042	36,705	40,990	45,756	51,056	56,949
Strontium ranelate	5,978	11,423	18,045	26,056	35,376	46,498	59,753	70,754	81,986	94,531	108,094	122,816	138,858
Raloxifene	28,702	34,834	42,195	51,036	61,144	73,250	87,755	98,094	108,711	121,133	134,948	150,310	167,391
Raloxifene*	23,530	26,724	29,717	32,260	33,937	34,770	34,674	32,877	30,604	28,135	25,528	22,892	20,314

Cost per QALY (£) for women aged 80 – 84 (Figure 7)

T-Score	-5	-4.5	-4	-3.5	-3	-2.5	-2	-1.5	-1	-0.5	0	0.5	1
Absolute Risk	9.98%	7.62%	5.85%	4.53%	3.52%	2.76%	2.23%	1.89%	1.61%	1.39%	1.20%	1.04%	0.90%
Alendronate	-7,592	-4,643	-924	3,762	9,429	16,470	24,386	32,277	41,138	51,486	63,077	76,018	90,443
Risedronate	-5,357	-2,031	2,117	7,286	13,452	21,038	29,381	37,413	46,348	56,749	68,341	81,246	95,609
Etidronate	5,573	7,506	9,859	12,725	15,998	19,957	23,903	27,097	30,687	35,010	39,882	45,371	51,555
Strontium ranelate	529	4,977	10,463	17,229	25,183	34,887	45,296	54,918	65,562	77,972	91,779	107,147	124,266
Raloxifene	22,272	27,876	34,697	43,004	52,482	63,951	75,381	84,630	95,029	107,561	121,683	137,594	155,518
Raloxifene*	20,093	24,251	28,745	33,385	37,541	41,214	43,201	43,089	42,233	40,801	38,693	36,058	33,064

\* indicates that breast cancer effects were included

**Data for figures 8 to 14 in the Addendum to the Assessment Report: cost-effectiveness of interventions by absolute annual fracture risk for women with a previous fracture but no other clinical risk factors**

Cost per QALY (£) for women aged 50 – 54 (Figure 8)

T-Score	-5	-4.5	-4	-3.5	-3	-2.5	-2	-1.5	-1	-0.5	0	0.5	1
Absolute Risk	11.97%	7.06%	4.43%	2.99%	2.17%	1.67%	1.36%	1.14%	0.97%	0.87%	0.82%	0.78%	0.75%
Alendronate	-5,652	-2,085	4,184	14,616	30,645	52,971	80,813	112,160	144,963	173,995	191,700	206,363	219,117
Risedronate	-4,189	466	8,343	20,761	38,542	61,401	87,814	115,898	144,431	169,073	183,248	195,361	206,283
Etidronate	42,667	48,574	55,084	62,335	70,382	79,421	89,588	101,030	113,910	125,258	130,658	136,278	142,125
Strontium ranelate	-154	7,594	20,248	39,245	64,869	95,873	129,959	165,157	200,645	231,036	247,853	262,654	276,375
Raloxifene	122,960	139,681	158,112	178,642	201,427	227,022	255,809	288,207	324,679	356,810	372,101	388,014	404,570
Raloxifene*	33,305	30,923	28,250	25,480	22,744	20,135	17,704	15,480	13,472	11,667	10,055	8,645	7,414
Teriparatide**	217,570	247,181	279,825	316,188	356,915	402,655	454,100	512,000	577,184	634,330	661,523	689,824	719,270
Teriparatide	6,772	21,444	46,495	86,377	144,216	219,443	307,327	401,676	498,257	581,769	629,886	671,079	708,265

Cost per QALY (£) for women aged 55 – 59 (Figure 9)

T-Score	-5	-4.5	-4	-3.5	-3	-2.5	-2	-1.5	-1	-0.5	0	0.5	1
Absolute Risk	10.22%	6.45%	4.30%	3.03%	2.26%	1.77%	1.43%	1.19%	1.01%	0.92%	0.86%	0.81%	0.76%
Alendronate	-4,775	-610	5,932	15,579	28,699	45,158	64,273	85,215	107,421	122,923	135,452	146,824	157,539
Risedronate	-2,859	2,353	10,177	21,088	35,037	51,544	69,855	89,373	109,880	123,525	134,567	144,840	154,747
Etidronate	22,928	26,487	30,495	35,037	40,141	45,953	52,578	60,133	68,749	73,631	77,850	82,301	86,994
Strontium ranelate	2,207	10,242	21,690	36,729	54,841	75,252	97,202	120,325	144,695	160,268	172,969	185,102	197,066
Raloxifene	67,119	77,194	88,542	101,403	115,853	132,311	151,070	172,460	196,856	210,681	222,628	235,230	248,519
Raloxifene*	29,442	28,670	27,330	25,572	23,533	21,362	19,167	17,030	15,008	13,079	11,343	9,804	8,444
Teriparatide**	136,203	156,567	179,508	205,505	235,062	268,725	307,099	350,864	400,787	428,897	453,188	478,812	505,833
Teriparatide	10,987	26,119	49,115	81,569	123,722	174,228	230,914	291,965	356,663	399,496	434,279	466,782	498,231

Cost per QALY (£) for women aged 60 – 64 (Figure 10)

T-Score	-5	-4.5	-4	-3.5	-3	-2.5	-2	-1.5	-1	-0.5	0	0.5	1
Absolute Risk	9.31%	6.18%	4.29%	3.11%	2.34%	1.83%	1.47%	1.21%	1.04%	0.94%	0.87%	0.80%	0.74%
Alendronate	-3,541	503	6,585	15,305	27,038	41,975	59,953	80,624	101,118	117,016	131,900	146,029	159,743
Risedronate	-1,482	3,489	10,641	20,375	32,761	47,724	64,974	84,235	102,726	116,392	129,311	141,790	154,136
Etidronate	22,848	26,724	31,168	36,282	42,071	48,752	56,467	65,378	73,622	78,882	84,506	90,517	96,941
Strontium ranelate	3,931	11,542	22,045	35,704	52,318	71,662	93,403	117,371	139,966	156,089	171,583	186,828	202,169
Raloxifene	66,864	77,838	90,421	104,901	121,291	140,208	162,053	187,286	210,629	225,524	241,447	258,468	276,659
Raloxifene*	32,297	31,986	30,953	29,331	27,266	24,947	22,520	20,101	17,729	15,477	13,452	11,646	10,045
Teriparatide**	122,709	142,786	165,807	192,301	222,852	258,124	298,870	345,956	389,641	417,168	446,596	478,052	511,670
Teriparatide	13,545	27,946	48,968	77,978	115,660	161,840	215,756	276,610	335,468	378,685	419,731	459,518	498,984

Cost per QALY (£) for women aged 65 – 69 (Figure 11)

T-Score	-5	-4.5	-4	-3.5	-3	-2.5	-2	-1.5	-1	-0.5	0	0.5	1
Absolute Risk	9.68%	6.84%	4.99%	3.75%	2.90%	2.29%	1.85%	1.51%	1.33%	1.20%	1.09%	0.99%	0.91%
Alendronate	-3,701	131	5,397	12,367	21,168	31,930	44,681	59,438	71,627	83,172	94,585	105,984	117,536
Risedronate	-1,513	3,016	9,010	16,640	25,915	36,903	49,613	64,099	75,500	86,214	96,888	107,672	118,734
Etidronate	12,525	14,934	17,742	21,020	24,788	29,194	34,349	40,382	44,306	48,145	52,303	56,806	61,683
Strontium ranelate	3,911	10,248	18,289	28,120	39,657	52,981	68,155	85,337	98,218	110,323	122,560	135,117	148,176
Raloxifene	37,653	44,476	52,425	61,707	72,374	84,850	99,447	116,529	127,641	138,509	150,283	163,035	176,845
Raloxifene*	25,024	26,423	27,220	27,353	26,796	25,665	24,078	22,180	19,890	17,658	15,564	13,628	11,863
Teriparatide**	82,830	97,708	115,042	135,283	158,948	186,639	219,053	257,006	281,887	305,827	331,760	359,848	390,266
Teriparatide	14,266	26,840	43,812	65,803	93,197	126,180	164,874	209,502	244,663	277,582	310,599	344,137	378,675

Cost per QALY (£) for women aged 70 – 74 (Figure 12)

T-Score	-5	-4.5	-4	-3.5	-3	-2.5	-2	-1.5	-1	-0.5	0	0.5	1
Absolute Risk	11.01%	8.20%	6.23%	4.82%	3.80%	3.03%	2.45%	2.05%	1.81%	1.62%	1.45%	1.31%	1.18%
Alendronate	-3,375	-177	3,802	8,658	14,370	21,087	28,913	36,936	43,717	50,833	58,182	65,839	73,890
Risedronate	-1,297	2,210	6,448	11,485	17,274	23,976	31,706	39,481	45,843	52,567	59,564	66,916	74,712
Etidronate	6,665	8,161	9,931	12,027	14,424	17,261	20,619	23,861	26,231	28,935	31,902	35,159	38,732
Strontium ranelate	3,307	7,737	12,970	19,085	26,016	33,997	43,195	52,314	59,548	67,308	75,481	84,166	93,465
Raloxifene	21,064	25,302	30,313	36,248	43,034	51,064	60,571	69,749	76,459	84,115	92,517	101,739	111,857
Raloxifene*	17,110	19,238	21,189	22,805	23,858	24,340	24,203	23,230	21,547	19,750	17,886	16,022	14,210
Teriparatide**	45,974	55,039	65,760	78,457	93,505	111,349	132,515	153,086	168,355	185,116	203,512	223,701	245,854
Teriparatide	12,556	21,590	32,873	46,681	63,300	83,054	106,341	130,062	149,622	170,022	191,441	214,100	238,248

Cost per QALY (£) for women aged 75 – 79 (Figure 13)

T-Score	-5	-4.5	-4	-3.5	-3	-2.5	-2	-1.5	-1	-0.5	0	0.5	1
Absolute Risk	12.62%	9.59%	7.38%	5.74%	4.52%	3.58%	2.87%	2.46%	2.15%	1.88%	1.66%	1.47%	1.31%
Alendronate	-4,738	-1,955	1,454	5,603	10,490	16,333	23,299	29,551	35,983	43,046	50,589	58,672	67,369
Risedronate	-2,600	436	4,080	8,437	13,477	19,431	26,466	32,517	38,678	45,461	52,724	60,536	68,984
Etidronate	5,266	6,601	8,202	10,124	12,322	14,953	18,106	20,353	22,661	25,359	28,361	31,698	35,409
Strontium ranelate	1,872	5,675	10,191	15,546	21,678	28,903	37,429	44,425	51,522	59,424	67,949	77,194	87,264
Raloxifene	17,586	21,455	26,097	31,668	38,038	45,664	54,800	61,313	68,000	75,823	84,523	94,196	104,952
Raloxifene*	15,377	17,924	20,530	23,044	25,128	26,749	27,735	27,095	25,923	24,458	22,715	20,791	18,777
Teriparatide**	38,616	46,881	56,794	68,694	82,989	100,164	120,806	135,870	151,415	168,703	187,928	209,305	233,072
Teriparatide	9,958	17,522	26,946	38,583	52,841	70,194	91,206	109,349	128,151	148,457	170,421	194,243	220,166

Cost per QALY (£) for women aged 80 – 84 (Figure 14)

T-Score	-5	-4.5	-4	-3.5	-3	-2.5	-2	-1.5	-1	-0.5	0	0.5	1
Absolute Risk	14.51%	11.15%	8.62%	6.71%	5.25%	4.13%	3.36%	2.87%	2.46%	2.12%	1.84%	1.60%	1.40%
Alendronate	-8,986	-6,754	-4,009	-629	3,387	8,287	13,715	19,043	24,942	31,753	39,311	47,690	56,980
Risedronate	-7,257	-4,807	-1,824	1,818	6,093	11,270	16,888	22,219	28,085	34,855	42,351	50,655	59,865
Etidronate	2,396	3,633	5,138	6,970	9,065	11,599	14,124	16,167	18,464	21,228	24,343	27,852	31,805
Strontium ranelate	-2,707	451	4,269	8,899	14,272	20,750	27,624	33,899	40,791	48,787	57,651	67,490	78,431
Raloxifene	13,062	16,648	21,011	26,324	32,386	39,722	47,032	52,947	59,598	67,610	76,639	86,811	98,270
Raloxifene*	12,145	15,104	18,436	22,078	25,631	29,142	31,606	32,483	32,835	32,749	32,031	30,726	28,928
Teriparatide**	28,639	36,236	45,481	56,737	70,444	87,135	104,030	118,072	133,896	151,727	171,820	194,457	219,958
Teriparatide	3,426	9,462	17,045	26,547	38,419	53,210	69,515	85,143	102,685	122,317	144,246	168,718	196,022

\* indicates that breast cancer effects were included

\*\* indicates that the effect on hip fracture was excluded